Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| amfAR, The Foundation for AIDS Research | OTHER |
Not provided
Not provided
Not provided
Not provided
The study is a pre-implementation cross-sectional study exploring chemsex behaviors among transgender persons and gathering perspectives from multiple stakeholders to inform the development of transgender-tailored harm reduction services.
This study is designed under the EPIS framework (Exploration and Preparation phases) to better understand chemsex use among transgender populations in Thailand.
The study aims to:
Data will be collected using a mixed-methods approach, including:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Transgender Chemsex Users | Transgender women and transgender men who are current or former chemsex users. Participants will take part in semi-structured in-depth interviews (IDIs) exploring chemsex behaviors, patterns of use, perceived impacts, and needs for transgender-tailored harm reduction services. |
| |
| Family Members, Friends, or Partners | Family members, friends, or partners of transgender persons who have not engaged in chemsex. Participants will provide perspectives on the social, behavioral, and relational impacts of chemsex and support needs. |
| |
| Stakeholders | Stakeholders including healthcare providers, policy makers, law enforcement officers, counselors, public health professionals, and community leaders involved in care, policy, or regulation related to chemsex. Participants will be interviewed to identify system-level facilitators and barriers to implementation of services. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Understanding of chemsex patterns, impacts, and service needs among transgender persons | Behavioral | : During study period (single visit within ~12 months study duration) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Key themes on chemsex behaviors and service needs | Qualitative themes identified from semi-structured in-depth interviews, including:
| At interview (single time point) |
| Barriers and facilitators to implementation of transgender-tailored chemsex services | Barriers and facilitators to implementation identified using the Consolidated Framework for Implementation Research (CFIR) domains based on stakeholder and participant interviews. | At interview (single time point) |
| Chemsex-related behavioral and demographic characteristics | Descriptive characteristics of participants, including demographic data, substance use patterns, and behavioral risk factors collected via questionnaire. | At interview (single time point) |
| HIV-related stigma score | HIV-related stigma will be assessed using the HIV Stigma Scale (HSS). The HSS is a validated instrument measuring multiple domains of stigma, including personalized stigma, disclosure concerns, negative self-image, and concerns with public attitudes. The total score ranges from 40 to 160, with higher scores indicating greater levels of HIV-related stigma (worse outcome) Score (range: 40-160) | Baseline, Month 3, Month 6 |
| Transgender-related stigma score | Transgender-related stigma will be measured using the Transgender Identity Survey (TIS) (or instrument used in the protocol). This scale assesses experiences of stigma, discrimination, and internalized transphobia. Unit of Measure: Score (range: 20-100) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
• Unable to participate in in-depth interview (IDI) (online or onsite)
transgender population focus
Not provided
G1: Transgender chemsex users
G2: Family / partners
G3: Stakeholders
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nittaya Phanuphak, MD,PhD. | Contact | 6681 825 3544 | nittaya.p@ihri.org | |
| Rena Janamnuaysook, MBA | Contact | 662 160 5371 | rena.j@ihri.org |
| Name | Affiliation | Role |
|---|---|---|
| Nittaya Phanuphak, MD,PhD. | Institute of HIV Research and Innovation (IHRI) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tangerine Clinic, Institute of HIV Research and Innovation | Recruiting | Pathum Wan | Bangkok | 10330 | Thailand |
Not provided
Not provided
Not provided
Not provided
| Baseline, Month 3, Month 6 |
| PrEP adherence (self-reported adherence score) | Self-reported adherence will be measured using a standardized adherence questionnaire assessing the number of doses taken over the past 30 days. Scores range from 0 to 100%, with higher percentages indicating better adherence (better outcome). In addition, adherence will be objectively assessed using tenofovir diphosphate (TFV-DP) concentrations in dried blood spots. Unit of Measure: Percentage (%) Drug concentration (fmol/punch) | Baseline, Month 3, Month 6 |
| Intervention acceptability score | Description: Acceptability will be assessed using the System Usability Scale (SUS). The SUS is a 10-item questionnaire with scores ranging from 0 to 100, with higher scores indicating better usability and acceptability (better outcome). Score (range: 0-100) | Month 3 |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D012749 | Sexually Transmitted Diseases |
| D000099004 | Chemsex |
| D040261 | Harm Reduction |
| ID | Term |
|---|---|
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012725 | Sexual Behavior |
| D001519 | Behavior |
Not provided
Not provided